Context Therapeutics (NASDAQ:CNTX – Get Rating) and Aadi Bioscience (NASDAQ:AADI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.
Valuation & Earnings
This table compares Context Therapeutics and Aadi Bioscience’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Context Therapeutics||N/A||N/A||-$10.46 million||N/A||N/A|
|Aadi Bioscience||$1.12 million||320.49||-$110.09 million||($12.64)||-1.36|
This table compares Context Therapeutics and Aadi Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
20.4% of Context Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Aadi Bioscience shares are held by institutional investors. 7.1% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings for Context Therapeutics and Aadi Bioscience, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Context Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 306.09%. Aadi Bioscience has a consensus target price of $47.25, suggesting a potential upside of 175.51%. Given Context Therapeutics’ higher possible upside, equities analysts plainly believe Context Therapeutics is more favorable than Aadi Bioscience.
Context Therapeutics Company Profile (Get Rating)
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. Context Therapeutics Inc. was founded in 2015 and is based in Philadelphia, Pennsylvania.
Aadi Bioscience Company Profile (Get Rating)
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.